Frederick, MD — August 5, 2025 — Leads & Copy — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) announced the granting of inducement awards to two new employees on August 4, 2025. The company issued options to purchase 5,750 shares of common stock at an exercise price of $12.48 per share. These options, approved by the board of directors, vest as to 25% on August 4, 2026, and then in three equal annual installments, fully vesting on August 4, 2029, with a ten-year term. The awards were granted under Nasdaq Rule 5635(c)(4) as an inducement for employment.
Cartesian Therapeutics is a clinical-stage company focused on cell therapy for autoimmune diseases. Its lead asset, Descartes-08, is in Phase 3 clinical development for generalized myasthenia gravis and Phase 2 for systemic lupus erythematosus, with a Phase 2 basket trial planned for additional autoimmune indications. Descartes-15, a next-generation anti-BCMA CAR-T, is in a Phase 1 trial for multiple myeloma.
Megan LeDuc, Associate Director, Investor Relations, megan.leduc@cartesiantx.com; David Rosen, Argot Partners, david.rosen@argotpartners.com
Source: Cartesian Therapeutics
